دورية أكاديمية
Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters.
العنوان: | Characterization of Omicron BA.4.6, XBB, and BQ.1.1 subvariants in hamsters. |
---|---|
المؤلفون: | Halfmann PJ; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, 53711, USA., Iwatsuki-Horimoto K; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan., Kuroda M; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, 53711, USA., Hirata Y; Department of Pathology, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Yamayoshi S; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan.; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, 162-8655, Japan., Iida S; Department of Pathology, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Uraki R; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan.; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, 162-8655, Japan., Ito M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan., Ueki H; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan.; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, 162-8655, Japan., Furusawa Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan.; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, 162-8655, Japan., Sakai-Tagawa Y; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan., Kiso M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan., Armbrust T; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, 53711, USA., Spyra S; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, 53711, USA., Maeda K; Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan., Wang Z; Department of Animal, Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, 84322, USA., Imai M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan.; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, 162-8655, Japan., Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo, 162-8640, Japan. tksuzuki@nih.go.jp., Kawaoka Y; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, 53711, USA. yoshihiro.kawaoka@wisc.edu.; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, 108-8639, Japan. yoshihiro.kawaoka@wisc.edu.; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, 162-8655, Japan. yoshihiro.kawaoka@wisc.edu.; The University of Tokyo, Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), Tokyo, 162-8655, Japan. yoshihiro.kawaoka@wisc.edu. |
المصدر: | Communications biology [Commun Biol] 2024 Mar 15; Vol. 7 (1), pp. 331. Date of Electronic Publication: 2024 Mar 15. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN: 2399-3642 (Electronic) Linking ISSN: 23993642 NLM ISO Abbreviation: Commun Biol Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: London, United Kingdom : Nature Publishing Group UK, [2018]- |
مواضيع طبية MeSH: | Biological Assay* , DNA Replication*, Animals ; Cricetinae ; Female ; Humans ; Male ; Animals, Genetically Modified ; Mesocricetus ; Mutation |
مستخلص: | During the Omicron wave, previous variants such as BA.2, BA.4, and BA.5 were replaced by newer variants with additional mutations in the spike protein. These variants, BA.4.6, BQ.1.1, and XBB, have spread in different countries with different degrees of success. Here, we evaluated the replicative ability and pathogenicity of BA.4.6, BQ1.1, and XBB clinical isolates in male Syrian hamsters. Although we found no substantial differences in weight change among hamsters infected with these Omicron subvariants, the replicative ability of BQ.1.1 and XBB in lung tissue was higher than that of BA.4.6 and BA.5. Of note, BQ.1.1 was lethal in both male and female transgenic human ACE2 hamsters. In competition assays, XBB replicated better than BQ.1.1 in the nasal turbinate tissues of female hamsters previously infected with Omicron BA.2. These results suggest that newer Omicron subvariants in the XBB family are still evolving and should be closely monitored. (© 2024. The Author(s).) |
References: | Panahi, Y. et al. An overview on the treatments and prevention against COVID-19. Virol. J. 20, 23 (2023). (PMID: 10.1186/s12985-023-01973-9367553279906607) Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234–236 (2022). (PMID: 10.1016/S0140-6736(21)02844-034942101) Takashita, E. et al. In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6. N. Engl. J. Med. 387, 2094–2097 (2022). (PMID: 10.1056/NEJMc221184536383452) Imai, M. et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N. Engl. J. Med. 388, 89–91 (2023). (PMID: 10.1056/NEJMc221430236476720) Kurhade, C. et al., Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med. https://doi.org/10.1038/s41591-022-02162-x (2022). Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell https://doi.org/10.1016/j.cell.2022.12.018 (2022). Arora, P. et al., Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(22)00831-3 (2023). Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. USA 117, 16587–16595 (2020). (PMID: 10.1073/pnas.2009799117325719347368255) Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834–838 (2020). (PMID: 10.1038/s41586-020-2342-5324083387394720) Yuan, L. Z. et al., Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. Sig. Transduct. Target. Thar. 6, 136 (2021). Plunkard, J. et al. SARS-CoV-2 Variant Pathogenesis Following Primary Infection and Reinfection in Syrian Hamsters. mBio 14, e0007823 (2023). (PMID: 10.1128/mbio.00078-2337036339) Uraki, R. et al. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 isolates in rodents. Nature 612, 540–545 (2022). (PMID: 10.1038/s41586-022-05482-736323336) Gilliland, T. et al. Transchromosomic bovine-derived anti-SARS-CoV-2 polyclonal human antibodies protects hACE2 transgenic hamsters against multiple variants. iScience 26, 107764 (2023). (PMID: 10.1016/j.isci.2023.1077643773603810509298) Uraki, R. et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. Nature 607, 119–127 (2022). (PMID: 10.1038/s41586-022-04856-13557697210579982) Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279–286.e278 (2023). (PMID: 10.1016/j.cell.2022.12.018365809139747694) Su, W. et al., Omicron BA.1 and BA.2 sub-lineages show reduced pathogenicity and transmission potential than the early SARS-CoV-2 D614G variant in Syrian hamsters. J. Infect. Dis. https://doi.org/10.1093/infdis/jiac276 (2022). Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687–692 (2022). (PMID: 10.1038/s41586-022-04441-6350620158942849) Chen, D. Y. et al., Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. Nature https://doi.org/10.1038/s41586-023-05697-2 (2023). van Doremalen, N. et al. SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta. Sci. Adv. 8, eade1860 (2022). (PMID: 10.1126/sciadv.ade1860363995669674298) Ito, J. et al., Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. bioRxiv https://doi.org/10.1101/2022.12.05.519085 (2022). Karyakarte, R. P. et al., Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant. Cureus J. Med. Sci. 15, e35261 (2023). Golden, J. W. et al. Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. mBio 13, e0290621 (2022). (PMID: 10.1128/mbio.02906-2135073750) Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, https://doi.org/10.1038/s41586-022-04441-6 (2022). Kawaoka, Y. et al. Characterization of SARS-CoV-2 Omicron BA.4 and BA.5 clinical isolates. Res. Square, https://doi.org/10.21203/rs.3.rs-1820048/v1 (2022). Quick, J. nCoV-2019 sequencing protocol. Protocol.io https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye?version_warning=no (2020). Itokawa, K., Sekizuka, T., Hashino, M., Tanaka, R. & Kuroda, M. Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR. PLoS One 15, e0239403 (2020). (PMID: 10.1371/journal.pone.0239403329465277500614) Itokawa, K. et al. nCoV-2019 sequencing protocol for illumina V.5 https://www.protocols.io/view/ncov-2019-sequencing-protocol-for-illumina-b2msqc6e?version_warning=no (2021). |
معلومات مُعتمدة: | 75N93021C00014 United States AI NIAID NIH HHS |
تواريخ الأحداث: | Date Created: 20240316 Date Completed: 20240318 Latest Revision: 20240319 |
رمز التحديث: | 20240319 |
مُعرف محوري في PubMed: | PMC10943235 |
DOI: | 10.1038/s42003-024-06015-w |
PMID: | 38491227 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2399-3642 |
---|---|
DOI: | 10.1038/s42003-024-06015-w |